The content on this site is intended for healthcare professionals only
Dr Yelena Janjigian speaks to cancer about the CheckMate 649 study. This study investigated nivolumab (NIVO) plus chemotherapy (Chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/oesophageal adenocarcinoma.
Initially, she explains the background and the design of the study. Dr Janjigian then discusses the results of the study and what impact it can have on the future treatment of gastric cancers.
She concludes by mentioning that NIVO + chemo continued to demonstrate clinically meaningful long-term survival benefit vs chemo and an acceptable safety profile with additional follow-up, further supporting its use as a new standard 1L treatment in patients with advanced GC/GEJC/EAC.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
ASCO 2024: Lung cancer highlights
ASCO 2024: Lung cancer roundup
Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
OncoAlert round up July 28th to August 3rd, 2023
Adjuvant nivolumab vs placebo in resected oesophageal or gastroesophageal junction cancer following chemo: Biomarker analysis
Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer
ATTRACTION-5: Nivolumab plus chemotherapy as postoperative adjuvant treatment for pStage III G/GEJ cancer
NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy in locally advanced rectal cancer
